Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Peking University308 enrolled

Overview

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Ripretinib has become the standard ≥ 4L treatment in advanced GIST. Given the small sample size of patients in the China bridging study of INVICTUS as well as the short marketing time of ripretinib, further exploration on the long-term efficacy and safety of ripretinib, as well as the dominant gene mutation type of ripretinib in Chinese GIST patients is required. Hence, we plan to further explore the efficacy of ripretinib, predictors of efficacy, etc. by collecting and analyzing real-world data from Chinese patients with advanced GIST recieving ripretinib.

Study Type

OBSERVATIONAL

Enrollment

308

Conditions

Gastrointestinal Stromal Tumors

Interventions

Ripretinib Oral TabletDRUG

Oral kinase inhibitor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -≥18 years old * Histologically confirmed gastrointestinal stromal tumor (GIST) * At least one measurable lesion (mRECIST v1.1) * Received or receiving ripretinib treatment Exclusion Criteria: * Patients who received \<1 cycle of ripretinib treatment * Medical records are incomplete

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

PFS

To assess the efficacy (progression-free survival \[PFS\]

Time frame: approximately 7 months

Secondary Outcomes

DCR

To assess disease control rate (DCR)

Time frame: approximately 6 months

to assess median overall survival (mOS)

Time frame: approximately 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.